As these transcriptional alterations suggest a reduction in hepatic fibrosis in response to lowering oxalate via AGXT overexpression, we next evaluated hepatic fibrosis through histopathological and immunofluorescence analyses coupled with biochemical verification. This evidence concerns the gene AGXT and fibrosis.